Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers Squibb (BMY) is a trending stock that has underperformed recently, with shares down 6.5% over the past month against the S&P 500's 2.9% gain. Despite this, the biopharmaceutical company has consistently surpassed consensus EPS and revenue estimates for the last four quarters. While current fiscal year EPS is forecast to jump significantly (+465.2%), subsequent periods show projected declines in both EPS and revenue, contributing to a Zacks Rank #3 (Hold) and a valuation that suggests it trades at a discount to peers.

Analysis

Bristol Myers Squibb (BMY) presents a conflicting fundamental picture, characterized by significant recent stock underperformance juxtaposed with a history of strong operational execution. Over the past month, the stock has declined 6.5%, lagging both the S&P 500's 2.9% gain and its industry's 0.8% loss. This price action contrasts with the company's track record of beating consensus EPS and revenue estimates for the last four consecutive quarters, including a notable +36.45% EPS surprise and a +7.66% revenue surprise in its most recent report. However, forward-looking estimates are the primary source of concern. While the current fiscal year's consensus EPS is projected to rise an anomalous 465.2%, subsequent forecasts turn negative. For the current quarter, analysts expect an 8.3% year-over-year EPS decline and a 1% revenue contraction. More importantly, projections for the next fiscal year indicate a 6.6% drop in EPS and an 8.4% decline in revenue. This deteriorating outlook, despite stable analyst estimates over the past 30 days, has led to a neutral Zacks Rank #3 (Hold) but also contributes to a Zacks Value Style Score of 'A', suggesting the stock is trading at a discount to its peers.

Key Decisions for Investors

• Value-oriented investors may find the stock's 'A' grade for value and recent price weakness attractive, but must weigh this against the significant headwinds from projected revenue and earnings declines in the next fiscal year.
• Given consensus estimates for revenue to fall 2.1% in the current fiscal year and 8.4% in the next, investors seeking growth should be cautious as the company's top-line is expected to contract.
• The stock's Zacks Rank #3 (Hold) suggests it may perform in line with the market, making it prudent for current holders to monitor for any future changes to analyst estimates, which have remained stagnant despite the negative forward-looking trends.